A
Alcista
Alcista · 25%AXGN
$13.56
Precio del escenario
$34.620
-0.980 (-2.83%)Al cierre
Loading chart…
- Máximo
- 35.650
- Apertura
- 35.630
- Precio medio ponderado por volumen
- 34.89
- Volumen
- 1.14M
- Capitalización
- 315.55M
- Mínimo
- 34.400
- Importe
- 39.89M
- EV/EBITDA, TTM
- -878.35
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Análisis de IA of AxoGen, Inc. (AXGN)
MantenerAxoGen Inc is currently priced at $34.62, with a forward P/E of 102.04 indicating high future earnings expectations. However, the RSI is at a low 22.42, suggesting the stock is oversold and may rebound. The primary risk is the significant insider selling, which has increased by 768.09% over the last month, indicating potential lack of confidence from insiders.
Recomendaciones de analistas (6)
+14.96% de potencial alcista
Comprar
6 Comprar
0 Mantener
0 Vender
Actual: 34.62
Mínimo
39.00
Promedio
39.80
Máximo
40.00
BofA
Comprar
$52
2026-10-12
BofA
2026-10-12
Precio objetivo
$52
Comprar
Barclays
Sobreponderar
$55
2026-10-06
Barclays
2026-10-06
Precio objetivo
$55
Sobreponderar
Truist
Comprar
$53
2026-10-01
Truist
2026-10-01
Precio objetivo
$53
Comprar
Raymond James
Superar al mercado
$53
2026-09-25
Raymond James
2026-09-25
Precio objetivo
$53
Superar al mercado
Truist
Comprar
$60
2026-08-26
Truist
2026-08-26
Precio objetivo
$60
Comprar
Métricas de valoración
El PER previsto actual de AxoGen, Inc. (AXGN) es 102.04, frente a su media de 5 años de 115.15.
Escenarios de precio de Alphio AI para AXGN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con AXGN en cartera
Cronología de eventos
Noticias
6.010-12CNBCMorgan Stanley Sees Growth Potential for eBay
4.510-03NewsfilterTech Stocks Propel Nasdaq Gains Amid Mixed Market Performance
8.509-11NASDAQ.COMBiotech Sector Updates: Acquisitions and Partnerships
8.509-10NASDAQ.COMAxogen Acquires BioCircuit Technologies for $200 Million
8.509-10NASDAQ.COMAxogen Acquires BioCircuit Technologies for $200 Million
Preguntas frecuentes sobre AXGN, respondidas por Alphio AI
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
AxoGen Inc is currently priced at $34.62, with a forward P/E of 102.04 indicating high future earnings expectations. However, the RSI is at a low 22.42, suggesting the stock is oversold and may rebound. The primary risk is the significant insider selling, which has increased by 768.09% over the last month, indicating potential lack of confidence from insiders.
6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.